Results 71 to 80 of about 23,036 (202)
Use of Polyamidoamine Dendrimers in Brain Diseases
Molecules, 2018 Polyamidoamine (PAMAM) dendrimers are one of the smallest and most precise nanomolecules available today, which have promising applications for the treatment of brain diseases. Each aspect of the dendrimer (core, size or generation, size of cavities, and
Maria Florendo +6 more
doaj +1 more source
Advanced Healthcare Materials, Volume 15, Issue 36, 25 September 2026.Mitochondria‐targeted nanotherapies emerge as a promising strategy for combating aging‐associated neurodegenerative disorders (NDs) by restoring mitochondrial function, reducing oxidative stress, and improving neuronal survival. Recent advances in nanotechnology, therapeutic delivery, and translational research are highlighted, providing insights into ...
Dnyandev G. Gadhave +8 more
wiley +1 more source
Novel Aldehyde-Terminated Dendrimers; Synthesis and Cytotoxicity Assay
BioImpacts, 2012 Introduction: Polyamidoamine (PAMAM) dendrimers are a unique family of dendritic polymers with numerous pharmaceutical and biomedical applications. One major problem with these polymers is their cytotoxicity.
Mohammad-Reza Rashidi +5 more
doaj +1 more source
Nanomaterials, 2017 One of the most studied nanocarriers for drug delivery are polyamidoamine (PAMAM) dendrimers. However, the alterations produced by PAMAM dendrimers in neuronal function have not been thoroughly investigated, and important aspects such as effects on ...
Felipe Vidal +8 more
doaj +1 more source
Bacteria‐Responsive Nanostructured Drug Delivery Systems for Targeted Antimicrobial Therapy
Advanced Materials, Volume 38, Issue 51, 11 September 2026.Bacteria‐responsive nanocarriers are designed to release antimicrobials only in the presence of infection‐specific cues. This selective activation ensures drug release precisely at the site of infection, avoiding premature or indiscriminate release, and enhancing efficacy.
Guillermo Landa +3 more
wiley +1 more source
The Structure of PAMAM DAB-dendr(NH2)4 – the First Crystal Structure of a PAMAM-Dendrimer [PDF]
, 2020 The first crystal structure of an amino terminated PAMAM-dendrimer (DABdendr(NH2)4) is reported. The structure features a compact dendrimer conformation without voids, held together by intermolecular hydrogen bonds between ...
Joern, Christensen, Jesper, Bendix
core +1 more source
Predicting cytotoxicity of PAMAM dendrimers using molecular descriptors
Beilstein Journal of Nanotechnology, 2015 The use of data mining techniques in the field of nanomedicine has been very limited. In this paper we demonstrate that data mining techniques can be used for the development of predictive models of the cytotoxicity of poly(amido amine) (PAMAM ...
David E. Jones +2 more
doaj +1 more source
Journal of Pharmacy & Pharmaceutical Sciences, 2018 Purpose: The antibacterial activity of some antibiotics is specific to either Gram-positive or Gram-negative bacteria. There are different mechanisms behind such insensitivities like inability of antibiotics to permeate through some bacterial membranes,
Azadeh Serri +3 more
doaj +1 more source
Lactoferrin and Nanotechnology: New Insights Into Glioblastoma Therapy
CNS Neuroscience &Therapeutics, Volume 32, Issue 9, September 2026.Current glioblastoma multiforme (GBM) management primarily relies on surgery, chemotherapy, and radiotherapy; however, therapeutic efficacy remains limited due to tumor invasiveness and restricted drug penetration across the blood–brain barrier. Lactoferrin (LF), an iron‐binding glycoprotein with receptor‐mediated transport capability, has emerged as a
Atena Abed, Javad Amini Mahabadi
wiley +1 more source
MedComm – Biomaterials and Applications, Volume 5, Issue 3, September 2026.The image illustrates how PROTACs utilize endocytosis, mediated by cell surface proteins, to overcome bioavailability limitations and enable efficient intracellular delivery. ABSTRACT Proteolysis‐targeting chimeras (PROTACs) are promising therapeutic agents for targeted protein degradation via the ubiquitin‐proteasome system; however, their clinical ...
Huahua Chen +3 more
wiley +1 more source